ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of $0.20, $0.01 better than the analyst estimate of $0.19. Revenue for the quarter came in at $139.16 million versus the consensus estimate of $139.85 million.

GUIDANCE:

ADMA Biologics sees FY2026 revenue of ~$635 million, versus the consensus of $635 million.

ADMA Biologics sees FY2027 revenue of ~$775 million, versus the consensus of $775 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.